Biomarkers of Synaptic Damage in Multiple Sclerosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorNeuromed IRCCS
About this trial
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.
Eligibility criteria
Qualifiers
Male and female patients (age between 18 and 65 years)
Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,
EDSS between 0 and 5.5 (included),
Patients able to provide informed consent to participation in the study
Disqualifiers
Inability to provide informed written consent
Altered basal blood count
Pregnancy or lactation
Contraindications for the execution of magnetic resonance imaging with gadolinium
Trial design
Treatments tested in this trial
- lumbar puncture
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
Neuromed IRCCS
Lead sponsor
IRCCS Multimedica
Collaborator
Source ClinicalTrials.gov